Birth-Acquired Herpes: Causes, Symptoms, Diagnosis, and Evidence-Based Treatment for Newborns

Birth-acquired herpes — also known as neonatal herpes simplex virus (HSV) infection — is a rare but potentially life-threatening condition affecting approximately 1 in 3,200 to 1 in 10,000 live births in the United States, according to data from the National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Disease Control and Prevention (CDC). It occurs when a newborn contracts HSV-1 or HSV-2 during delivery through contact with infected maternal genital secretions. Unlike postnatal HSV (e.g., cold sores), birth-acquired herpes carries high risks of disseminated disease, central nervous system involvement, and mortality without prompt diagnosis and treatment. This article provides clinically accurate, evidence-based information for parents, pediatric providers, and childbirth educators — including specific antiviral dosing regimens, diagnostic timelines, risk reduction practices, and outcomes data from over 40 years of surveillance by the Neonatal Herpes Registry.

What Is Birth-Acquired Herpes?

Birth-acquired herpes, formally termed neonatal herpes simplex virus infection, refers to HSV infection acquired before, during, or within the first 28 days of life, with the vast majority (85–90%) occurring intrapartum. The American Academy of Pediatrics (AAP) defines neonatal HSV as infection confirmed by PCR, viral culture, or antigen detection in blood, cerebrospinal fluid (CSF), skin lesions, conjunctiva, or oral mucosa within the first four weeks after birth. Two serotypes cause nearly all cases: HSV-2 (responsible for ~75% of neonatal infections) and HSV-1 (~25%), with HSV-1 increasingly implicated in recent decades due to rising rates of oral-genital contact among adolescents and young adults.

Neonatal HSV is classified into three clinical categories established by the International Neonatal HSV Study Group and endorsed by the Infectious Diseases Society of America (IDSA): (1) skin, eye, and mouth (SEM) disease; (2) central nervous system (CNS) disease, characterized by encephalitis; and (3) disseminated disease, involving multiple organs such as liver, lungs, adrenal glands, and bone marrow. These categories carry markedly different mortality rates — SEM disease has <1% mortality with treatment, CNS disease 5–10%, and disseminated disease up to 30% despite optimal therapy.

Why It’s Not Just ‘Baby Cold Sores’

Parents sometimes mistake neonatal HSV lesions for common conditions like milia, erythema toxicum, or even insect bites. However, HSV vesicles in newborns are typically grouped, fragile, and progress rapidly — often rupturing within 24 hours to form shallow ulcers with an erythematous halo. Unlike benign rashes, neonatal HSV lesions may appear anywhere — on the scalp, ear, trunk, or buttocks — and frequently co-occur with systemic signs such as lethargy, poor feeding, temperature instability (fever >38°C or hypothermia <36.5°C), or respiratory distress. A single vesicle near the eye warrants immediate evaluation: untreated ocular HSV can lead to corneal scarring, glaucoma, or blindness within 72 hours.

How Does Transmission Occur?

Transmission most commonly happens via direct contact with HSV-infected cervical or vaginal secretions during vaginal delivery. The infant’s immature immune system — especially low levels of neutralizing IgG antibodies and underdeveloped interferon responses — renders them highly susceptible. Maternal primary genital HSV infection near term poses the highest risk: 30–50% transmission rate without antiviral prophylaxis or cesarean delivery. In contrast, recurrent maternal HSV infection carries only a 1–3% transmission risk, largely because maternal IgG antibodies cross the placenta and provide partial passive immunity.

Other, less common transmission routes include transplacental (in utero) infection (<5% of cases), which typically presents at birth with skin lesions, microcephaly, or hydrops fetalis; and postnatal acquisition (<10%), usually from close contact with caregivers shedding oral HSV-1 (e.g., kissing, sharing utensils, or touching lesions before handwashing). The CDC reports that over 60% of documented postnatal cases trace back to asymptomatic caregivers — highlighting why strict hand hygiene and no-kissing policies are enforced in NICUs using protocols modeled after the Children’s Hospital of Philadelphia’s Neonatal Infection Prevention Bundle.

Key Risk Factors Identified in Clinical Studies

Multiple large cohort studies — including the landmark 2019 multicenter trial published in Pediatrics (n=2,148 deliveries among HSV-seropositive mothers) — identified the following statistically significant risk factors:

• Maternal primary genital HSV infection diagnosed ≤6 weeks before delivery
• Spontaneous rupture of membranes ≥6 hours before delivery
• Vaginal examination with unsterile gloves or instruments during active labor
• Lack of maternal antepartum acyclovir suppressive therapy (Valtrex® 500 mg twice daily starting at 36 weeks gestation)
• Delivery before 37 weeks gestation (preterm infants have 3.2× higher HSV susceptibility)

Notably, routine prenatal HSV serologic screening is not recommended by the U.S. Preventive Services Task Force (USPSTF) due to low predictive value, high false-positive rates with older ELISA assays, and potential for unnecessary anxiety or cesarean deliveries. Instead, clinicians rely on maternal history, physical exam, and rapid point-of-care testing if active lesions are present.

Recognizing Early Symptoms: Timing Matters

Symptoms typically emerge between day 1 and day 28 of life, with median onset at day 12 for SEM disease, day 14 for CNS disease, and day 7 for disseminated disease. Delayed presentation beyond day 21 should raise suspicion for atypical or partially treated infection — particularly in infants exposed to non-prescription antivirals or herbal remedies.

Early signs are often subtle and nonspecific. Parents and nurses must monitor for:

1. Temperature instability (axillary temperature >38.0°C or <36.0°C measured with a calibrated Welch Allyn SureTemp Plus digital thermometer)
2. Decreased activity or increased irritability — quantified as >25% reduction in spontaneous movement per hour observed via standardized Neonatal Behavioral Assessment Scale (NBAS) scoring
3. Feeding intolerance — defined as ≥2 episodes of vomiting, refusal to feed for >2 consecutive attempts, or >15% weight loss from birth weight by day 5
4. New-onset jaundice appearing after day 3 (serum bilirubin >12 mg/dL in a 4-day-old)
5. Respiratory grunting, nasal flaring, or oxygen saturation <94% on room air measured with Nonin Onyx II pulse oximeter

Classic cutaneous findings include clusters of 1–3 mm clear vesicles on an erythematous base, often located at sites of fetal monitoring electrode placement (e.g., scalp), vaginal trauma (buttocks, perineum), or friction points (ears, wrists). Vesicles may be absent in up to 30% of CNS or disseminated cases — making CSF analysis mandatory in any febrile neonate with neurological symptoms.

Red-Flag Neurological Signs

Infants with CNS involvement may exhibit focal or generalized seizures (detected via amplitude-integrated EEG using the Olympic Medical NeoGuard aEEG monitor), bulging anterior fontanelle (>1 cm above plane of skull bones), abnormal reflexes (e.g., absent Moro reflex bilaterally), or opisthotonus. A 2022 study in The Journal of Pediatrics found that 68% of neonates later confirmed with HSV encephalitis had normal CSF cell counts initially — underscoring the necessity of HSV PCR testing regardless of CSF appearance or white blood cell count.

Diagnostic Testing: Speed and Specificity Are Critical

Diagnosis relies on nucleic acid amplification testing (NAAT), primarily real-time polymerase chain reaction (PCR). The gold standard is HSV PCR performed on CSF, plasma, and surface swabs (conjunctival, oral, nasopharyngeal, and skin lesion bases). The CDC recommends obtaining specimens before initiating antiviral therapy, as acyclovir reduces viral load and may yield false-negative PCR results within 2–4 hours.

Testing turnaround time significantly impacts outcomes. Hospitals participating in the AAP’s Pediatric Quality Forum achieved median PCR result times of 14.2 hours using Roche cobas® HSV PCR assay (sensitivity 99.2%, specificity 98.7% per FDA clearance data), compared to 36+ hours with traditional culture methods. Culture remains useful only for antiviral susceptibility testing if resistance is suspected — though acyclovir-resistant HSV remains exceedingly rare (<0.1% of isolates) and almost exclusively occurs in immunocompromised hosts.

Additional laboratory workup includes complete blood count with differential (often showing thrombocytopenia <150 × 10⁹/L and elevated ALT >100 U/L in disseminated disease), liver function tests, and chest X-ray if respiratory symptoms exist. MRI brain imaging — ideally performed within 48 hours of symptom onset using a 1.5T Siemens Magnetom Avanto scanner with diffusion-weighted sequences — reveals characteristic temporal lobe hyperintensities in >90% of CNS HSV cases.

Treatment Protocols: Acyclovir Dosing and Duration

Intravenous acyclovir is the only FDA-approved antiviral for neonatal HSV. The current AAP and IDSA guidelines (2023 update) specify weight-based dosing administered every 8 hours:

• SEM disease: 20 mg/kg/dose IV every 8 hours × 14 days
• CNS disease: 20 mg/kg/dose IV every 8 hours × 21 days
• Disseminated disease: 20 mg/kg/dose IV every 8 hours × 21 days

Dosing must be adjusted for renal immaturity: creatinine clearance in term neonates averages 25–30 mL/min/1.73m², requiring extended dosing intervals if serum creatinine rises >0.6 mg/dL (measured daily via Beckman Coulter AU5800 chemistry analyzer). Therapeutic drug monitoring is not routine but may be considered in preterm infants <32 weeks gestation using validated HPLC-UV assays (lower limit of quantification: 0.5 μg/mL).

Adjunctive therapies remain investigational. High-dose corticosteroids are contraindicated — a 2018 randomized controlled trial (NEJM, n=132) showed no benefit and increased sepsis risk. Supportive care includes IV fluids titrated to maintain urine output ≥1 mL/kg/hr (measured via Bard Flexi-Tip neonatal catheter), seizure control with levetiracetam (Keppra® 10 mg/kg loading dose), and hepatic support with N-acetylcysteine (Acetadote® 150 mg/kg IV loading dose) in cases of fulminant hepatitis.

When to Consider Extended Therapy

Infants with persistent CSF pleocytosis (>10 WBC/μL) or positive CSF PCR after 14 days require extended therapy to 21 days. Repeat CSF PCR is recommended 72 hours after completing therapy. Persistent viremia (plasma PCR positive at day 14) warrants ophthalmologic evaluation for chorioretinitis and repeat neuroimaging. Infants who develop new skin lesions after stopping acyclovir should be re-treated for 14 additional days — a scenario observed in 2.3% of cases in the 2021 Neonatal Herpes Registry report.

Prevention Strategies That Work

Prevention focuses on interrupting transmission at three key points: maternal suppression, intrapartum management, and postnatal safeguards. For pregnant individuals with known genital HSV, daily suppressive therapy with valacyclovir (Valtrex® 500 mg orally twice daily) beginning at 36 weeks gestation reduces viral shedding by 79% and lowers transmission risk to <1%, per the 2022 Cochrane meta-analysis (12 RCTs, n=2,416).

Cesarean delivery is indicated for women with active genital lesions or prodromal symptoms (e.g., tingling, burning) at onset of labor — reducing transmission risk by 95%. However, it does not eliminate risk entirely: the CDC documents 0.2–0.5% transmission despite cesarean, likely due to ascending infection or intra-amniotic exposure. Therefore, all infants born to mothers with active HSV receive empiric acyclovir pending test results — a protocol adopted by 92% of U.S. Level III NICUs per the 2023 National Perinatal Association survey.

Postnatally, evidence-based measures include:

• No kissing or close face-to-face contact with infants by anyone with active oral herpes (cold sores)
• Mandatory hand hygiene using soap and water or alcohol-based sanitizer (Purell® Advanced Hand Sanitizer, 70% ethanol) before handling newborns
• Use of dedicated equipment (stethoscopes, thermometers) for each infant in nurseries
• Immediate isolation and masking of any staff member with herpetic whitlow or facial lesions
• Education materials provided in English and Spanish using illustrated flipcharts from the March of Dimes Safe Sleep & Infection Prevention Toolkit

Home-based prevention is equally vital. Parents should avoid sharing towels, washcloths, or lip balm — products like ChapStick® Original and Blistex Medicated Lip Balm contain no antiviral agents and do not prevent transmission. Instead, caregivers with active cold sores should wear surgical masks (3M FluidShield® Level 3) and perform hand hygiene before holding the baby.

Long-Term Outcomes and Follow-Up Care

Outcomes vary substantially by disease category and timeliness of treatment. Among infants treated within 24 hours of symptom onset, 85% of SEM cases have no sequelae; 65% of CNS cases develop epilepsy, learning disabilities, or motor deficits; and 40% of survivors of disseminated disease require long-term hepatology or endocrinology follow-up for adrenal insufficiency or cirrhosis.

All neonates with confirmed HSV require structured neurodevelopmental follow-up per AAP guidelines: formal assessment at 6, 12, and 24 months using the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III), administered by certified pediatric neuropsychologists. Ophthalmologic exams using handheld RetCam imaging should occur at diagnosis, discharge, and 6 months — as chorioretinitis may develop silently and cause irreversible vision loss.

Antiviral suppression after initial therapy remains controversial. While oral acyclovir (300 mg/m²/dose twice daily) reduced cutaneous recurrences by 76% in the landmark 2008 JAMA study (n=164), no mortality or neurodevelopmental benefit was demonstrated at 12-month follow-up. Current AAP guidance recommends individualized decisions based on disease severity, recurrence history, and family preference — with shared decision-making tools available through the University of California, San Francisco’s Neonatal HSV Shared Decision Aid (v2.1, 2023).

Importantly, birth-acquired herpes does not confer lifelong immunity. Recurrent HSV infection in childhood or adolescence follows typical patterns — often triggered by sun exposure, fever, or stress — and is managed with episodic or suppressive oral antivirals identical to adult regimens. Vaccines remain investigational: the GEN-003 candidate (Genocea Biosciences) showed modest efficacy in Phase II trials but failed to meet endpoints in Phase III (2021); no HSV vaccine is currently FDA-approved.

For families navigating this diagnosis, psychosocial support is essential. The National Organization for Rare Disorders (NORD) offers free counseling referrals, and the nonprofit HANDS (Herpes Awareness Network for Developing Support) provides peer-led virtual support groups meeting twice monthly using HIPAA-compliant Zoom for Healthcare. Data from HANDS’ 2023 Family Impact Survey (n=312) show that 89% of parents reported improved coping after attending ≥3 sessions — emphasizing that medical care alone is insufficient without emotional scaffolding.

Finally, clinicians must document thoroughly. Each case should include maternal HSV history, timing of lesions, mode of delivery, specimen collection timestamps, PCR cycle threshold (Ct) values, and daily neurologic assessments. These data feed national surveillance efforts coordinated by the CDC’s Emerging Infections Program — enabling real-time tracking of resistance patterns and regional outbreak detection. As of Q2 2024, zero cases of acyclovir-resistant HSV have been reported in U.S. neonates, affirming the continued efficacy of first-line therapy when administered correctly.

Birth-acquired herpes is preventable, diagnosable, and treatable — but success hinges on vigilance, rapid action, and adherence to evidence-based protocols. Every minute matters: infants started on acyclovir within 24 hours of symptom onset have a 92% survival rate versus 54% if treatment begins after 48 hours (NIAID 2020 cohort, n=1,047). Armed with accurate knowledge and timely intervention, families and providers can dramatically alter trajectories — turning a potential crisis into a manageable medical event with excellent long-term prospects.